Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
DBTX Stock Summary
In the News

Decibel Therapeutics' CVR Appears Around Fair Value
Decibel Therapeutics is being acquired by Regeneron for a cash consideration of $4/share and a CVR linked to DB-OTO. DB-OTO is a gene therapy for hearing loss, with a phase 1/2 trial underway. The CVR broadly pays out with the early stages of the Phase III trial and subsequently the filing of a BLA application (or European equivalent).

Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals
Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline.

Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This deal has Regeneron Pharmaceuticals agreeing to acquire Decibel Therapeutics for $4 per share in cash.

Decibel Therapeutics shoots up 72% on Regeneron bid
Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be a knock-out bid for the tiny drug developer. The deal values Decibel Therapeutics, which is working on treatments aimed at enhancing and restoring hearing and balance, at $109 million.

Regeneron buying small cap Decibel Therapeutics for $4 a share
Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its closing price of $2.79 a share in the previous session. Boston-based Decibel Therapeutics is a clinical-stage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance.

Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Los Angeles, California May 16 – 20th, 2023.

Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.

Decibel Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September.

Top Penny Stocks Today? 3 You Might Want To Watch Before Next Week
Penny stocks to watch before the end of the week. The post Top Penny Stocks Today?
DBTX Financial details
DBTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -4.98 | -5.61 | -1.63 | -2.38 | -2.52 | |
Operating cash flow per share | -4.97 | -6.72 | -1.41 | -1.99 | -2.28 | |
Free cash flow per share | -5.15 | -6.81 | -1.42 | -2.02 | -2.3 | |
Cash per share | 11.33 | 4.39 | 2.35 | 6.84 | 4.19 | |
Book value per share | 7.92 | 2.15 | -7.04 | 6.52 | 3.28 | |
Tangible book value per share | 7.92 | 2.15 | -7.04 | 6.52 | 3.28 | |
Share holders equity per share | 7.92 | 2.15 | -7.04 | 6.52 | 3.28 | |
Interest debt per share | 0 | 0 | 0.22 | 0.2 | 0.61 | |
Market cap | 130.85M | 132.63M | 416.94M | 101.06M | 51.17M | |
Enterprise value | 119.53M | 114.03M | 389.39M | 64.82M | 30.61M | |
P/E ratio | -3.62 | -3.21 | -11.08 | -1.95 | -0.81 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.63 | -2.68 | -12.77 | -2.34 | -0.9 | |
PFCF ratio | -3.5 | -2.65 | -12.66 | -2.3 | -0.89 | |
P/B Ratio | 2.28 | 8.37 | -2.56 | 0.71 | 0.63 | |
PTB ratio | 2.28 | 8.37 | -2.56 | 0.71 | 0.63 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.29 | -2.69 | -9.84 | -1.33 | -0.49 | |
EV to operating cash flow | -3.31 | -2.31 | -11.92 | -1.5 | -0.54 | |
EV to free cash flow | -3.2 | -2.27 | -11.82 | -1.48 | -0.53 | |
Earnings yield | -0.28 | -0.31 | -0.09 | -0.51 | -1.23 | |
Free cash flow yield | -0.29 | -0.38 | -0.08 | -0.43 | -1.12 | |
Debt to equity | 0 | 0 | -0.03 | 0.03 | 0.17 | |
Debt to assets | 0 | 0 | 0.08 | 0.02 | 0.11 | |
Net debt to EBITDA | 0.31 | 0.44 | 0.7 | 0.74 | 0.33 | |
Current ratio | 7.6 | 3.55 | 2.98 | 7.99 | 4.81 | |
Interest coverage | 0 | 0 | 0 | 0 | -53.66 | |
Income quality | 1 | 1.16 | 0.83 | 0.83 | 0.9 | |
Dividend Yield | 0 | 0 | 0.13 | 0.27 | 0 | |
Payout ratio | 0 | 0 | -1.46 | -0.53 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0.01 | 0.01 | 0.02 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.87 | -0.41 | -0.17 | -0.53 | -0.32 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 29.79 | 16.49 | 16.05 | 18.7 | 13.64 | |
ROIC | -0.69 | -2.69 | 0.24 | -0.36 | -0.58 | |
Return on tangible assets | -0.39 | -0.96 | -0.56 | -0.28 | -0.51 | |
Graham Net | 6.4 | 0.72 | -7.56 | 5.27 | 2.52 | |
Working capital | 72.61M | 24.12M | 38.45M | 143.65M | 85.59M | |
Tangible asset value | 57.45M | 15.85M | -162.69M | 141.69M | 81.79M | |
Net current asset value | 47.78M | 6.58M | -172.15M | 121.4M | 66.45M | |
Invested capital | 0 | 0 | -0.03 | 0.03 | 0.17 | |
Average receivables | 0 | 0 | 618.5K | 6.32M | 5.7M | |
Average payables | 0 | 1.04M | 1.57M | 3.07M | 2.54M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.63 | -2.6 | 0.23 | -0.37 | -0.77 | |
Capex per share | -0.18 | -0.1 | -0.01 | -0.03 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.68 | -0.64 | -0.64 | -0.53 | -0.73 | |
Operating cash flow per share | -0.54 | -0.55 | -0.31 | -0.68 | -0.41 | |
Free cash flow per share | -0.54 | -0.55 | -0.32 | -0.69 | -0.41 | |
Cash per share | 5.03 | 4.48 | 4.19 | 3.52 | 3.13 | |
Book value per share | 4.48 | 3.88 | 3.28 | 2.79 | 2.13 | |
Tangible book value per share | 4.48 | 3.88 | 3.28 | 2.79 | 2.13 | |
Share holders equity per share | 4.48 | 3.88 | 3.28 | 2.79 | 2.13 | |
Interest debt per share | 0.62 | 0.6 | 0.59 | 0.51 | 0.51 | |
Market cap | 105.08M | 86.37M | 51.17M | 75.47M | 96.32M | |
Enterprise value | 64M | 64.41M | 30.61M | 50.8M | 69.36M | |
P/E ratio | -1.54 | -1.35 | -0.8 | -1.42 | -1.33 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -7.84 | -6.3 | -6.59 | -4.42 | -9.38 | |
PFCF ratio | -7.77 | -6.28 | -6.43 | -4.36 | -9.39 | |
P/B Ratio | 0.94 | 0.89 | 0.63 | 1.08 | 1.81 | |
PTB ratio | 0.94 | 0.89 | 0.63 | 1.08 | 1.81 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.82 | -4.03 | -1.9 | -3.69 | -3.71 | |
EV to operating cash flow | -4.77 | -4.7 | -3.94 | -2.98 | -6.76 | |
EV to free cash flow | -4.73 | -4.68 | -3.84 | -2.93 | -6.76 | |
Earnings yield | -0.16 | -0.19 | -0.31 | -0.18 | -0.19 | |
Free cash flow yield | -0.13 | -0.16 | -0.16 | -0.23 | -0.11 | |
Debt to equity | 0.14 | 0.15 | 0.17 | 0.19 | 0.24 | |
Debt to assets | 0.1 | 0.1 | 0.11 | 0.12 | 0.14 | |
Net debt to EBITDA | 2.45 | 1.37 | 1.28 | 1.79 | 1.44 | |
Current ratio | 6.18 | 5.4 | 4.81 | 4.14 | 3.03 | |
Interest coverage | -180.03 | -43.71 | -24.98 | 18.68 | 0 | |
Income quality | 0.79 | 0.86 | 0.49 | 1.28 | 0.57 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0.03 | 0.02 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.33 | -0.13 | -0.53 | -0.78 | 0.04 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.3 | 7.48 | 6.86 | 5.79 | 5.9 | |
ROIC | -0.12 | -0.13 | -0.15 | -0.15 | -0.24 | |
Return on tangible assets | -0.11 | -0.11 | -0.13 | -0.12 | -0.19 | |
Graham Net | 3.47 | 2.96 | 2.52 | 2.03 | 1.49 | |
Working capital | 118.53M | 102.91M | 85.59M | 72.69M | 53.87M | |
Tangible asset value | 111.86M | 96.81M | 81.79M | 69.84M | 53.31M | |
Net current asset value | 94.99M | 80.83M | 66.45M | 55.26M | 39.37M | |
Invested capital | 0.14 | 0.15 | 0.17 | 0.19 | 0.24 | |
Average receivables | 10M | 10M | 5M | 2.2M | 2.2M | |
Average payables | 1.56M | 2.47M | 2.05M | 1.17M | 947.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.15 | -0.17 | -0.19 | -0.19 | -0.34 | |
Capex per share | 0 | 0 | -0.01 | -0.01 | 0 |
DBTX Frequently Asked Questions
What is Decibel Therapeutics, Inc. stock symbol ?
Decibel Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol DBTX
What is Decibel Therapeutics, Inc. stock quote today ?
Decibel Therapeutics, Inc. stock price is $4.91 today.
Is Decibel Therapeutics, Inc. stock public?
Yes, Decibel Therapeutics, Inc. is a publicly traded company.